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Abstract  
Background and Purpose: Approaches to prevent selective and progressive loss of 
insulin-producing ß-cells in Type 1 diabetes mellitus (T1DM) will help conquer this 
prevalent and devastating disease. Curcumin (CUR), a natural anti-inflammatory, 
suppresses diabetes associated inflammation and cell death. However, very high doses 
have been tested owing to poor oral bioavailability, making it difficult to translate to the 
clinic. 
Experimental approach: We recently prepared biodegradable nanosystems 
encapsulating curcumin (nCUR), resulting in at least 9-fold improvement in oral 
bioavailability. In the current study, we tested nCUR’s ability to prevent streptozotocin 
(STZ)-induced inflammation and apoptosis in pancreatic islet/ß-cells. 
Key Results: Nonfasted rats pretreated with 10 or 50 mg/kg nCUR 6 hours prior to STZ 
challenge had up to 37% reduction in the glucose levels, while plain CUR (50 mg/kg) 
results in 12% reduction. This is owing to nCUR’s ability to prevent islet/-cell death 
evident from TUNEL assay, and H&E staining. Both CUR and nCUR significantly 
decreased levels of inflammatory cytokines in pancreatic tissue homogenates that 
correlated well with minimal histiocytic infiltration. The nCUR, rather than CUR pre-
treatment prevented 8-oxo-2'-deoxyguanosine (8-oxo-dG), a sensitive biomarker of 
reactive oxygen species (ROS)-induced DNA damage in pancreas. Our data in normal 
rodents indicates that 28 days daily dosing with nCUR (25 to 100 mg/kg) did not cause 
any deleterious health issues by the carrier.  
Conclusions & Implications: Together, these data indicate a potentially translatable 
dose of nCUR that is safe and efficacious in improving the ß-cell function, possibly 
preventing T1DM. 
Abbreviations: Allograft inflammatory factor 1 (AIF-1); Anti-interleukin-1β (anti-IL-1β); 
Bright field microscope (BFM); Curcumin (CUR); Dynamic light scattering system (DLS); 
Granulocyte-colony-stimulating factor (G-CSF); Granulocyte-macrophage colony-
stimulating factor (GM-CSF); Human Equivalent Doses (HED); Interferon gamma (IFNγ)  
Interleukin-1 beta (IL-1); Ionized calcium binding adaptor molecule 1 (Iba1); Nano-
curcumin (nCUR); 8-Oxo-2'-deoxyguanosine (8-oxo-dG); Pharmacodynamic (PD); 
Pharmacokinetic (PK); Polyvinyl alcohol (PVA); Rat pancreatic -insulinoma cells (RIN-
m5F); Reactive oxygen species (ROS); Streptozotocin (STZ); Terminal deoxynucleotidyl 
transferase (TdT) dUTP Nick-End Labeling (TUNEL); Tumor necrosis factor-alpha 
(TNF); Type 1 diabetes mellitus (T1DM). 
 
  
Table of Links 
LIGANDS  
Natural products or derivatives Cytokines and growth factors 
Curcumin TNF-alpha 
 IL-6 
 IL-1ß 
These  Tables  list  key  protein  targets  and  ligands  in  this  article  which  are  
hyperlinked  to corresponding  entries  in http://www.guidetopharmacology.org,  the  
common  portal  for  data from  the  IUPHAR/BPS  Guide  to  PHARMACOLOGY  
(Southan  et  al.,  2016)  and  are permanently archived in the Concise Guide to 
PHARMACOLOGY 2015/16 (Alexander et al., 2015). 
Introduction 
Type 1 diabetes mellitus (T1DM) is a heterogeneous disorder characterized by primary 
or secondary islet damage, making the beta () cells antigenic, prompting T-lymphocyte 
infiltration and production of pro-inflammatory cytokines, such as granulocyte-
macrophage colony-stimulating factor (GM-CSF), granulocyte-colony-stimulating factor 
(G-CSF), interleukin-1 beta (IL-1), tumor necrosis factor-alpha (TNF), and interferon 
gamma (IFNγ) (Atkinson, Eisenbarth & Michels, 2014; Eisenbarth, 1986; Hamilton, 
2008; Meah et al., 2016; Skyler, 2013). The clinical manifestations of T1DM are only 
evident when nearly 80% of the  cell mass has already been destroyed. To date there 
is no record of success with preventative strategies (Brooks-Worrell & Palmer, 2013; 
Reimann et al., 2009; Skyler, 2015; Skyler & Pugliese, 2013; Wherrett, 2014). Over the 
years, we have witnessed a plethora of developments in T1DM therapies that include 
insulin replacement, immunosuppression, antigen-specific and cell-based approaches. 
T1DM prevention in high risk individuals remains the highest priority where the goal is to 
maintain endogenous -cell function (Creusot, Battaglia, Roncarolo & Fathman, 2016; 
Li, Cheng & Zhou, 2016). Therefore, protection of -cells from cell death is considered 
as a new therapeutic target, (Ardestani & Maedler, 2016; Imai, Dobrian, Morris, Taylor-
Fishwick & Nadler, 2016; Roy, Janal, Crosby & Donnelly, 2016; Srimal & Dhawan, 
1973) where natural and safe anti-inflammatories, such as curcumin (CUR), (Castro et 
al., 2014; Srimal & Dhawan, 1973) can perform better than some of the biologics (e.g., 
Canakinumab, a fully human anti-interleukin-1β (anti-IL-1β) monoclonal antibody [IgG-
1κ class]) tested in trials with limited success (Cabrera et al., 2016). A critical barrier in 
the clinical translation of CUR is its limited oral bioavailability (Shaikh, Ankola, Beniwal, 
Singh & Kumar, 2009). We have recently reported several studies on CUR 
encapsulated nanosystem (nCUR) large scale preparation, and their therapeutic 
evaluation in models of diabetes complications (Grama et al., 2013; Grama, 
Venkatpurwar, Lamprou & Kumar, 2013; Ratnam, Wadsworth & Kumar, 2011). We 
herein report the ability of nCUR to prevent streptozotocin (STZ)-induced inflammation 
and apoptosis in pancreatic islet/-cells in rats, reflecting in a reduction of glucose levels 
and oxidative stress. 
Materials and Methods 
Streptozotocin (STZ) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and all 
other chemicals were obtained from Fisher Scientific (USA) unless otherwise 
mentioned. Curcumin (CUR) was purchased from Acros organics (New Jersey, USA). 
Antibodies were purchased from Thermo Fisher Scientific (Rockford, IL, USA), Santa 
Cruz (Dallas, Texas), Life technologies, USA and Cell Signaling, USA. DAPI was 
purchased from Vector Laboratories, USA, TUNEL was purchased from Roche 
Diagnostics (Mannhem, Germany). Rat insulin ELISA kits were purchased from 
Mercodia [10-1250-01] (Uppsala, Sweden), ProcartaPlex Rat Th complete panel was 
purchased from Affymetrix, eBiosciences (14plex EPX140-30120-901, USA) and, 
Histomount was purchased from Ted Pella Inc. RIN-m5f cells were purchased from 
ATCC and maintained in RPMI-1640 medium. 
Preparation and characterization of nCUR 
The nCUR were prepared as previously reported by our laboratory (Grama et al., 2013; 
Grama, Venkatpurwar, Lamprou & Kumar, 2013; Ratnam, Wadsworth & Kumar, 2011; 
Shaikh, Ankola, Beniwal, Singh & Kumar, 2009). In brief, polylactide-co-glycolide 
(PLGA) (500 mg) was dissolved in 20 mL of ethyl acetate, to which 75 mg CUR pre 
dissolved in 5 mL of ethyl acetate was added then stirred for 1 h at 1,000 rpm on a 
magnetic stirrer. This organic phase was added dropwise to 50 mL of 1% (w/v) polyvinyl 
alcohol (PVA) in water forming an oil-in-water emulsion followed by homogenization at 
16,000 rpm for 30 min. The emulsion was added to excess water (250 mL) and stirred 
overnight to evaporate organic solvent. The suspension was centrifuged at 15,000g for 
30 min at 4°C. The pellet was re-suspended in water (~15 mL). Sucrose (1.5 g) was 
dissolved separately in 5 mL of water then added to the re-suspended pellet with the 
entire suspension volume made to 30 mL. Two milliliters of the suspension was added 
per 5 mL vial and freeze dried. Three vials from the lot were used to measure particle 
size and CUR content using particle size analyzer [Brookhaven dynamic light scattering 
system (DLS)], and a previously developed HPLC method, respectively (Grama, 
Venkatpurwar, Lamprou & Kumar, 2013; Shaikh, Ankola, Beniwal, Singh & Kumar, 
2009). 
In vitro testing of nCUR in rat pancreatic -insulinoma cells (RIN-m5F) 
The RIN-m5f cells were cultured according to the cell bank protocol. The cells 
(5x104/well in 24-well plates) were pretreated with various concentrations of CUR or 
nCUR (10 & 20 M) for 1 h before challenging with 5 mM STZ (dissolved in citrate 
buffer, pH 4.5; containing trisodium citrate 0.1 M and citric acid 0.1 M) for 24h. The cells 
were washed twice with 1% BSA in PBS, 0.5 µg/mL propidium iodide (PI) was added 
before observation under an EVOS microscope. In another set of experiments, cells 
were fixed in 4% formaldehyde at room temperature for 30 min followed by washing 
with PBS. The effects of CUR/nCUR were evaluated by immunocytochemistry by 
staining fixed cells for caspase-8.  
Animal study 
All experimental procedures were approved by the Institutional Animal Care and Use 
Committee of the Texas A&M University, College Station (study-1, efficacy), or, of the 
University of Strathclyde, Glasgow under the Animals (Scientific Procedures) Act 1986 
(UK) (study-2, safety). Three month old male Sprague Dawley (SD) rats (250 ± 15 g, 
n=6) were used in study-1; two month old male SD rats (200 ± 15 g, n=4) were used in 
study-2. All animals were fed normal diet ad libitum throughout the studies. All end-point 
adjudication was blinded to dosing.  
Experimental protocol 
Study 1: After acclimatization for two weeks, the rats (male SD) were pre-treated with a 
single dose of CUR or nCUR (10 or 50 mg/kg) for 6 h prior to STZ challenge. All rats 
received a single intraperitoneal injection of 60 mg/kg STZ dissolved in 0.1 M sodium 
citrate buffer, pH 4.5 after 8h fasting. The  glucose levels in nonfasted rats were 
monitored at 24, 48, 72 h after STZ injection using precision Xtra glucometer (Abbott 
Diabetes Care Inc, Alameda, CA) and all rats were sacrificed at 72 h post STZ. The 
control groups received neither CUR nor STZ. Blood and pancreas were collected and 
processed for analysis of various markers, histological evaluation and 
immunohistochemistry. The study had the following six groups: Group 1 (Control); 
Group 2 (STZ) diabetic control (STZ 60mg/kg intraperitoneal injection); Group 3 (STZ + 
CUR10) 10mg/kg curcumin; Group 4 (STZ + CUR50) 50mg/kg curcumin; Group 5 (STZ 
+ nCUR10) 10mg/kg nano-curcumin; Group 6 (STZ + nCUR50) 50mg/kg nano-
curcumin. 
Study 2: After acclimatization for two weeks, the rats were treated with CUR 500 mg/kg 
or nCUR 25, 50, or 100 mg/kg daily by oral gavage for 28 days (Supplement Table S1). 
The control groups received equal volume of vehicle (water in this case), while nblank 
group received blank nanoparticles equivalent to the highest dose of CUR (100 mg/kg) 
for 28 days. Upon termination of the experiment at the end of 28 days, blood and other 
organs were collected and processed for hematological and histological analyses 
(detailed procedures and data are presented in Supplementary files). 
 
 
Blood collection and pancreas separation 
Rats in each group on Study-1 were sacrificed as per IACUC protocol at 72h; blood was 
collected via cardiac puncture in heparinized tubes and centrifuged at 1,620 g for 30 
min. The plasma was immediately stored at −80 °C for further use. The pancreas was 
surgically excised from the rats. These tissues were either stored at −80 °C until further 
analysis or fixed in 10% buffered formalin for histological assessment.  
Preparation of tissue homogenate 
A 10% pancreatic tissue homogenate was prepared using a probe sonicator (qsonica) 
at 30% amplitude for 30 secs, in ice cold homogenizing buffer (phosphate buffer/pH 7.4 
supplemented with protease and phosphatase inhibitors). The homogenates were spun 
down for 30 min at 20,817 g at 4 °C. The supernatant was collected and stored at −80 
°C until further use. 
Determination of plasma insulin 
Plasma insulin levels were determined by using rat insulin ELISA kits. 
Multiplex immunoassay for cytokines 
The cytokine panel of 14 markers was measured in plasma and pancreas homogenates 
using a Bio-Plex® MAGPIX™ Multiplex Reader multiplex immunoassay. The markers 
analyzed included IL-1 alpha, G-CSF, IL-10, IL-17A, IL-1 beta, IL-6, TNF-alpha, IL-4, 
GM-CSF, IFN-gamma, IL-2, IL-5, IL-13, IL-12p70. 
Histological studies 
Pancreas from normal and experimental rats were fixed in 10% neutral buffered 
formalin (NBF) and processed for routine histology and paraffin embedding. Four 
micrometer tissue sections were stained with hematoxylin and eosin and evaluated 
histologically to determine the degree of islet destruction. 
Immunohistochemistry to evaluate histiocytic infiltration in pancreatic islets  
Sections were incubated on a hot plate for 45-60 min at 60°C, followed by 
deparaffinizing in xylene for 5 min, and rehydration in decreasing grades of ethanol 
(100%, 95%, and 70%). Antigen retrieval was performed by boiling the sections using 
microwave, in 0.01M sodium-citrate buffer pH 6.0 for 10 mins and blocked with blocking 
solution (3% goat or horse serum in PBS). Slides were washed 3 times with PBS and 
incubated in PBS containing goat serum with (2µg/mL) anti-Iba1 antibody specific to 
human, mouse and rat microglia and macrophages at 4°C overnight. Slides were 
washed 3 times with PBS and the binding of primary antibodies visualized by the 
corresponding anti-Ig HRP detection kit according to the manufacturers’ instructions. 
Slides were counterstained with Mayer’s-hematoxylin (Sigma–Aldrich) and coversliped. 
Immunofluorescence of insulin, TUNEL, 8-oxo-dG 
Pancreases from normal and experimental rats were fixed in 10% NBF (24h), incubated 
in increased concentrations of sucrose solution (30%), in and stored in OCT medium at 
-80°C, until being processed for cryosectioning. Four micrometer cryosections were 
used for the immunohistochemical staining for insulin, and 8-oxo-dG.  
After antigen retrieval, cryosections were immunoreacted with respective primary 
antibodies (Abs) overnight at 4°C. All steps were preceded by rinsing with PBS (pH 7.4). 
Immunostaining was performed according to the standard protocol routinely used for 
immunohistopathology. Primary anti-insulin Ab [clone INS05 (2D11-H5)] was diluted to 
1:200. Primary monoclonal Ab to 8-hydroxyguanosine (8OHG), a marker of oxidative 
damage to nucleic acids was diluted to 1:200. Goat polyclonal anti-rabbit IgG 
conjugated with Alexa Fluor® 488 (green), 594 (red) were used as the secondary 
antibody at a dilution of 1:1000. All samples were mounted with Vectashield mounting 
medium containing DAPI. Goat polyclonal anti-mouse conjugated with Alexa Fluor® 594 
IgG was used as the secondary antibody for insulin detection at a dilution of 1:1000 in 
PBS. TUNEL was performed on the same sections using Terminal deoxynucleotidyl 
transferase (TdT) to label blunt ends of double stranded DNA breaks. The end-labeling 
method TUNEL (TdT-mediated X-dUTP nick end labeling) enables the highly sensitive 
detection of apoptosis in tissue (In Situ Cell Death Detection Kit).  
Image Analysis 
Images shown are representative of at least 3 rats which gave similar results. At least 
10 images were taken at the same magnification from all immunostained probes. 
Immunostained sections were examined on a Zeiss LSM780. Microscopy images were 
processed using ZEN2 image processing software. 
Statistics 
Results are expressed as mean ± SEMs (n = 6). Statistical analysis was performed 
using PRISM GRAPHPAD version 5.01. One-way analysis of variance (ANOVA) was 
used to compare multiple data sets and when the p value obtained from ANOVA was 
significant, Tukey's test was applied to test for differences among groups. Significance 
was considered to be p < 0.05. 
 
Results 
Preparation and characterization of nCUR 
The nCUR preparation process has been thoroughly optimized over the years in our 
laboratory (Grama et al., 2013; Shaikh, Ankola, Beniwal, Singh & Kumar, 2009). The 
preparation used in this study has a particle size of ~300 nm with ~100 g CUR/mg 
polymer (Supplement Fig. S1). These freeze dried preparations are rendered easy to 
reconstitute product with comparable characteristics to the fresh preparation in terms of 
size and CUR content in the particles. We have established shelf-storage stability of 
nCUR in our prior studies (Grama et al., 2013). 
In vitro testing of nCUR in rat pancreatic -insulinoma cells (RIN-m5F) 
Rat (RIN-m5F) insulinoma cells are widely used in vitro model for pancreatic β-cells 
(Skelin, Rupnik & Cencic, 2010), to study effects of STZ-induced cellular stress and 
apoptosis. Herein, we have used this model to test the ability of CUR and nCUR to 
protect STZ induced apoptosis. Untreated or RIN-m5F cells pretreated with CUR or 
nCUR for 1h were exposed to STZ for 24 h, and viability was assessed using PI assay, 
which stains dead cells. Treatment with STZ significantly reduced cell viability whereas, 
CUR and nCUR increased the viability of STZ-treated RIN-m5F cells (Fig. 1a). Similar 
effects of CUR and nCUR were observed on preventing caspase 8 activation, thereby 
preventing cell death and improving cell-survival (Fig. 1b).  
Multiplex immunoassay for cytokines 
Activated macrophages produce proinflammatory cytokines that are involved in up-
regulation of inflammatory reactions, promoting apoptosis. Therefore, we measured 
cytokine panel of 14 markers that include IL-1 alpha, G-CSF, IL-10, IL-17A, IL-1 beta, 
IL-6, TNF alpha, IL-4, GM-CSF, IFN gamma, IL-2, IL-5, IL-13, IL-12p70, in plasma and 
pancreas. STZ insult led to a significant increase in all the 14 markers studied. The 
nCUR was able to prevent the STZ-induced rise in G-CSF/GM-CSF (p<0.05), whereas 
CUR failed in the case of G-CSF. Both CUR and nCUR were successful in normalizing 
the proinflammatory cytokines in pancreas tissue homogenates (Fig. 2). However, the 
plasma analysis revealed no significant differences between controls, STZ or treatment 
groups for the studied duration [72h] (Supplement Table S2).  
Effect of CUR on blood glucose and plasma insulin level 
The selective pancreatic beta cell apoptosis caused by STZ challenge is expected to 
increase blood glucose levels, and a protection from -cell death should in principle 
have better glucose control. The nCUR, but not CUR, showed significant (p<0.05) 
reduction in blood glucose in nonfasted rats by 32% and 37% for nCUR10 and 
nCUR50, respectively, at 72h time point. The reduction in glucose levels also reflects in 
slight increase in plasma insulin levels, owing to improved ß-cell function (Fig. 3a). 
Interestingly, statistically significant differences were found in the glucose levels at 48 
and 72 h, suggesting possible ß-cell regeneration. However, more detailed experiments 
on repeated administration are needed for both pre-and post-STZ challenges. 
Effect of CUR on pancreatic islets/-cells 
Inflammation is associated with cell death and the ability to effectively target 
inflammatory pathways will prevent cell death (Santin & Eizirik, 2013) (Carrington, Kos, 
Zhan, Krishnamurthy & Allison, 2011). The ability of CUR/nCUR to prevent STZ induced 
-cell death was examined by TUNEL assay. The qualitative data clearly suggests that 
nCUR offered better protection than plain CUR treatment (Fig. 3b), and this was 
corroborated with plasma glucose levels (Fig. 3a). Immunostaining of insulin is shown in 
Supplement Fig. S2.  
The results of histological analysis of pancreas show well defined islets of Langerhans 
with intact exocrine of pancreatic tissues in normal control, which is lost in STZ control. 
Though there was as an improvement in both CUR and nCUR treated groups, the 
differences were statistically insignificant within (Fig. 4a). 
Histiocytes were identified by ionized calcium binding adaptor molecule 1 (Iba1), which 
is also called allograft inflammatory factor 1 (AIF-1). The immunohistochemical staining 
of Iba1 showed that the number of infiltrating histiocytes was significantly reduced with 
the CUR and nCUR treatments (p<0.05) (Fig. 4b).  
Under hyperglycemic condition, generation of reactive oxygen intermediates and 
apoptosis is expected to increase. Therefore, oxidative DNA damage was identified by 
immunostaining of 8-oxo-dG. A higher intensity of 8-oxodG was observed in diabetic 
pancreas, compared to control, while, nCUR was able to prevent the damage and CUR 
had little effect (Fig. 4c). 
Safety of CUR and nCUR on sub-acute dosing  
From a regulatory standpoint it is important to understand that the carrier systems do 
not cause any deleterious effects on the biological system. Repeated administration 
(daily for 28 days) of CUR at 500 mg/kg or nCUR at 25, 50 and 100 mg/kg or the CUR 
void nanosystems equivalent to 100 mg/kg CUR had no noticeable effects on 
inflammatory/oxidative stress, antioxidant enzyme levels or hematological parameters 
(Supplement Tables S3-S7). At 100 mg/kg in nCUR group showed significant increase 
in plasma levels as opposed to other groups (Supplement Table S8). Further, no 
noticeable changes were observed in histologic evaluation of examined rat tissues, 
including small intestine, spleen, lung, kidney, heart, testis etc. (Supplement Fig. S3). 
Discussion 
To the best of our knowledge, ours is the first study to demonstrate the ability of 
nCUR to prevent inflammation and -cell apoptosis. In doing so, we have also 
established the safety of the nanosystems, which is critical for clinical translation. 
Reformulating drugs or drug-like compounds to address stability, 
pharmacokinetic (PK)/pharmacodynamic (PD) issues is a common strategy and 
biodegradable nanosystems are hailed as breakthrough technology for this purpose 
(Bhardwaj et al., 2005). Despite the huge, largely untapped therapeutic benefit of CUR, 
a natural anti-inflammatory, numerous clinical trials have failed owing to poor oral 
bioavailability leading to reduced enthusiasm for CUR therapy (Kumar, 2012; Ratnam, 
Ankola, Bhardwaj, Sahana & Kumar, 2006; Ratnam, Wadsworth & Kumar, 2011). Our 
laboratory has conducted a series of investigations on improving CUR stability and oral 
bioavailability by encapsulating CUR into biodegradable nanosystems that led to 
improved efficacy in diabetes models (Shaikh, Ankola, Beniwal, Singh & Kumar, 2009; 
Grama et al., 2013; Grama, Venkatpurwar, Lamprou & Kumar, 2013; Ratnam, 
Wadsworth & Kumar, 2011).  
The current study describes the use of CUR nanosystems (nCUR) for preventing 
-cell apoptosis as a possible intervention for diabetes prevention and management. 
The nCUR used in this study have a particle size of ~300 nm with ~100 g CUR/mg 
polymer. Though there is no clear cut off size for oral delivery, it is generally believed 
smaller particle size is better absorbed (Ratnam, Bhardwaj & Kumar, 2013). Drug 
loading is critical for developing translatable dosage forms as initial loading and 
entrapment will influence the bio-distribution, safety and efficacy (Bhardwaj et al., 2005). 
This becomes really important for chronic conditions such as diabetes, in that, better 
drug loads will minimize excess use of excipients. According to USFDA, for 
conventional formulations, conversion of animal doses to Human Equivalent Doses 
(HED) based on body surface area requires animal dose in mg/kg to be divided by 6.2 
or multiplied by 0.16 to get HED in mg/kg. Based on these assumptions the HED of the 
dose used in this study will be 480 mg for a 60 kg human with ~4.8 g of associated 
polymer. Similar doses (360 mg/day, Trial #NCT02104752) of CUR nanosystems made 
of gum ghatti are currently in use clinical setting. Based on the preclinical studies in 
rodents, polymer nanosystems developed in the current study may not require daily 
administration; however this needs to be tested in higher animals or Phase 1 studies to 
better understand HED conversion of unconventional delivery systems. 
Effective prevention or management of diabetes requires the preservation of 
cells. A large body of data suggests that oxidative stress plays a key role in the 
development of diabetes and its complications (Acharya & Ghaskadbi, 2010). The weak 
defense status of islets combined with inefficiency in repairing oxidative DNA damage 
as compared to other tissues renders the pancreas vulnerable to oxidative stress 
leading to pancreatic -cell death.  STZ is a toxin that leads to oxidative 
stress/inflammation and apoptosis of -cells in the pancreas mimicking autoimmune 
diabetes.  In the present study, we used RINm5F cell line as a model of pancreatic β-
cells, to investigate CUR and nCUR’s ability to prevent STZ induced apoptosis. In 
general nCUR offered better cytoprotective properties compared to unformulated CUR, 
probably due to intracellular accumulation of nCUR and sustained release of 
encapsulated CUR (Prokop & Davidson, 2008). The current literature supports the role 
of caspase-8 in β-cell apoptosis leading to diabetes development (Choi, Schroer, Lu, 
Cai, Hao & Woo, 2011). The immunofluorescence observations of caspase-8 
corroborated with the PI assay. Pre-incubation of RINm5F cells with CUR or nCUR was 
able to prevent STZ induced cell death that was caused by activation of DNA 
endonuclease, resulting in apoptotic DNA fragmentation (Kruidering & Evan, 2000). 
To determine the protective effects of pretreating rats with CUR or nCUR 
followed by STZ insult, we examined changes in blood glucose and cytokines levels and 
correlated them with changes in pancreatic tissue function. We have analyzed 
granulocyte and granulocyte/macrophage colony stimulating factors (G-CSF and GM-
CSF) in plasma and pancreatic tissue homogenates. The cell sources for G-CSF 
include stroma, endothelium, fibroblasts, monocytes, and macrophages, and for GM-
CSF T lymphocytes, endothelium, fibroblasts, monocytes, macrophages and smooth 
muscle (Root & Dale, 1999). While the plasma levels were not significant between 
control and STZ groups, a significant increase in pancreatic tissue homogenates of STZ 
treated rats were observed. The systemic manifestation of inflammation could be 
duration dependent and such differences were also noticed by other workers (Kirwin, 
Kanaly, Linke & Edelman, 2009; Maier et al., 2008). In pancreatic tissue homogenates 
both CUR and nCUR were effective on reducing GM-CSF, while only nCUR was found 
to reduce G-CSF. Proinflammatory cytokines play a critical role in the series of events 
ultimately leading to tissue destruction in diabetes. Among others, proinflammatory 
cytokines are produced in macrophages and monocytes that triggers the differentiation 
of T-cells (IL-6) followed by a sequence of events such as, proliferation of cytotoxic T-
cells (IL-2), activation of T-cells and macrophages (IL-1, IFN-), infiltration of cells into 
tissues, local inflammation (TNF-) and local tissue destruction (IL-1) (Wang, Guan & 
Yang, 2010). The pretreatment with CUR or nCUR led to significant decreases in 
proinflammatory cytokine production which otherwise were increased in STZ groups. 
These findings are in agreement with an increase in histiocytic infiltration in STZ groups 
observed by immunohistochemical staining of Iba1. 
The blood glucose levels at 72 h were significantly lower in nCUR groups 
probably due to enhanced oral bioavailability of nCUR being more pronounced at 50 
mg/kg dose. This decrease in glucose was also reflected in a corresponding increase in 
insulin levels. These findings are in agreement with insulin immunofluorescence, islet 
numbers and the apoptotic cells determined by TUNEL. TUNEL positive cells in 
pancreatic islets increased notably in STZ group, while these numbers were 
dramatically reduced in rats pretreated with nCUR.  
It is widely recognized fact that macrophages are involved in the final stage of 
autoimmune-mediated β-cell destruction, where activated macrophages can directly kill 
β-cells (Yang, 2008). Oxidative damage is known to correlate well with -cell apoptosis 
and glucose levels in diabetes. Further, oxidative stress in diabetes is responsible for a 
cascade of events such as, stimulation of the polyol pathway, activation of protein 
kinase C, formation of advanced glycation end products, and subsequent formation of 
reactive oxygen radicals. Hyperglycemia, not only generates more reactive oxygen 
species, but also attenuates anti-oxidative mechanisms by scavenging enzymes and 
substances. We have examined oxidative DNA damage by 8-oxo-dG 
immunofluorescence where nCUR offered protection, but not CUR. The results from 
sub-acute toxicity study suggest nCUR at 100 mg/kg did not cause any deleterious 
general health effects attributable to the carrier. No significant hematological, 
histological or biochemical changes were recorded.  
In conclusion, this study demonstrates that nCUR is safe and prevents STZ-induced 
diabetes in rats, at least partly owing to the suppression of oxidative stress, 
inflammation and pancreatic -cell apoptosis. Further studies on repeated long-term 
administration and application to type-2 diabetes prevention will prove beneficial. It 
would also be interesting to see what insulin combined with nCUR could achieve in both 
type 1 and 2 diabetes management.  
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a) 
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Figure 1. Pre-treatment with CUR/nCUR prevents STZ induced cell death in RIN-
m5f cells. a) Cell death was identified by propidium iodide (PI) staining (20x 
magnification, scale bar represents 200µm). b) The presence of active caspase-8 was 
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examined by immunofluorescence using antibodies specific for cleaved caspase-8 (40x 
magnification, scale bar represents 100µm).  
 
 
 
Figure 2. Pre-treatment with CUR/nCUR (10 or 50 mg/kg) orally prior to STZ 
challenge regulates inflammatory cytokines. Pancreatic tissue homogenates were 
analyzed 72 h post STZ challenge using multiplex assay. CUR/nCUR regulated the 
expression of pro- and anti-inflammatory cytokines induced by STZ. Data are presented 
as mean ± SEM, (n=6) and were analyzed by one-way ANOVA, with Tukey's test. The 
treatment groups (STZ+10CUR, 50CUR, 10nCUR, 50nCUR) were compared with 
untreated diabetic controls (STZ) (*p<0.05, **p<0.01, ***p<0.001). 
a) 
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Figure 3. Pre-treatment with nCUR prior to STZ challenge protects against 
elevated blood glucose or insulin and loss of pancreatic islet cell numbers 
through apoptosis.  a) The blood glucose levels (24h, 48h and 72h) and 72h plasma 
insulin level post STZ challenge were monitored by glucose strips and ELISA kits (n=6). 
b) Pancreatic islets (72 h) were identified by insulin immunofluorescence (red), and 
apoptotic cells were determined by terminal deoxynucleotidyl transferase–mediated 
dUTP nick-end labeling (TUNEL) (green); nuclei were visualized by DAPI staining and 
shown in blue (n=6). Images were acquired using EVOIS-FL microscope at 40x 
magnification. Data are presented as the mean ± SEM, and were analyzed by one-way 
ANOVA, with Tukey's test. The treatment groups (STZ+10CUR, 10nCUR, 50CUR, 
50nCUR) were compared with untreated diabetic controls (STZ) (*P<0.05, **P<0.01, 
***P<0.001). 
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Figure 4. Pre-treatment with CUR/nCUR prior to STZ challenge supports 
pancreatic islet cell numbers while reducing histiocytic infiltration and oxidative 
stress. a) Histological changes in pancreatic tissue were observed by hematoxylin and 
eosin staining. Images were captured using bright field microscope (BFM) at 10x 
magnification and islets were marked in black dotted ellipses. The average number of 
islets per field at 10x magnification was plotted, (n=6). b) Histiocytes were identified by 
Iba1 immunohistochemistry using DAB (brown) and counterstained with hematoxylin. 
Images were acquired at 40x magnification using BFM. Histiocytic infiltration as a 
percentage of field of view area was calculated by NIH-imageJ software. Data are 
presented as mean ± SEM, (n= 6-12 images from each group) and were analyzed by 
one-way ANOVA, with Tukey's test. The treatment groups (STZ+10CUR, 50CUR, 
10nCUR, 50nCUR) were compared with untreated diabetic controls (STZ) (***P<0.001). 
c) Oxidative stress was identified by 8-oxo-dG immunofluorescent staining with FITC 
(green) and nuclei are counterstained with DAPI. Immunostained sections were 
examined on a Zeiss microscope. Microscopy images were captured using CLSM at 
40x original magnification for entire layout. Confocal images were processed using ZEN 
software. 
 
